Skip to main content

Advertisement

Log in

Cilostazol suppresses neointimal hyperplasia in canine vein grafts

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

To investigate whether cilostazol, a cyclic adenosine monophosphate (cAMP) phosphodiesterase inhibitor, suppresses intimal hyperplasia in canine vein grafts, and to elucidate its mechanisms in terms of cell proliferation and apoptosis.

Methods

Bilateral reversed jugular vein interposition grafts of the common carotid artery were performed in 12 beagle dogs. Starting from 7 days before surgery, either cilostazol (30 mg/day; n = 6) or a placebo (n = 6) was given orally twice daily. Vein grafts were harvested at 1 or 4 weeks, and fixed under pressure for histological examination.

Results

By 1 week after implantation, the cilostazol group showed significantly less cell proliferation than the placebo group. By 4 weeks after implantation, intimal and medial thickness was significantly thinner in the cilostazol group than in the placebo group. There was significantly more apoptosis in the placebo group than in the cilostazol group at both time points.

Conclusion

Cilostazol suppressed the development of intimal hyperplasia in canine autogenous vein grafts. Thus, it may be associated with the modulation of cell proliferation and apoptosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Taylor LM, Edwards JM, Porter JM. Present status of reversed vein bypass grafting: Five-year results of a modern series. J Vasc Surg 1990;11:193–206.

    Article  PubMed  Google Scholar 

  2. Bergamini TM, Towne JB, Bandyk DF, Seabrook GR, Schmitt DD. Experience with in situ saphenous vein bypasses during 1981 to 1989: Determinant factors of long-term patency. J Vasc Surg 1991;13:137–149.

    Article  PubMed  CAS  Google Scholar 

  3. Donaldson MC, Mannick JA, Whittemore AD. Femoral-distal bypass with in situ greater saphenous vein: Long-term results using the Mills valvulotome. Ann Surg 1991;213:457–464.

    Article  PubMed  CAS  Google Scholar 

  4. Nishi T, Tabusa F, Tanaka T, Shimizu T, Kanbe T, Kimura Y, et al. Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. II: 6-[3-(1-Cyclohexyl-5-tetrazolyl)-propoxy]-1,2-dihydro-2-oxoquinoline and related compounds. Chem Pharm Bull 1983;31:1151–1157.

    PubMed  CAS  Google Scholar 

  5. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung/Drug Res 1985;35:1144–1149.

    CAS  Google Scholar 

  6. Tanaka K, Gotoh F, Fukuuchi Y, Amano T, Uematsu D, Kawamura J, et al. Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the microcirculation in feline cerebral ischemia. Stroke 1989;20:668–673.

    PubMed  CAS  Google Scholar 

  7. Ikeda U, Ikeda M, Kano S, Kanbe T, Shimada K. Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells. Eur J Pharmacol 1996;14:197–202.

    Article  Google Scholar 

  8. Kubota Y, Kichikawa K, Uchida H, Maeda M, Nishinine K, Makutani S, et al. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study. Invest Radiol 1995;30:532–537.

    Article  PubMed  CAS  Google Scholar 

  9. Tsuchikane E, Katoh O, Sumitsuji S, Fukuhara A, Funamoto M, Otsuji S, et al. Impact of cilostazol on intimal proliferation after directional coronary atherectomy. Am Heart J 1998;135:495–502.

    Article  PubMed  CAS  Google Scholar 

  10. Tsuchikane E, Furuhara A, Kobayashi T, Kirino M, Yamasaki K, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 1999;100:21–26.

    PubMed  CAS  Google Scholar 

  11. Makutani S, Kichikawa K, Uchida H, Maeda M, Konishi N, Hiasa Y, et al. Effect of antithrombotic agents on the patency of PTFE-covered stents in the inferior vena cava: An experimental study. Cardiovasc Intervent Radiol 1999;22:232–238.

    Article  PubMed  CAS  Google Scholar 

  12. Fuxian Z, Nishibe T, Yasuda K, Yingli J, Changming Z, Zuotian M. Effect of cilostazol on endothelial cell loss and growth in canine vein grafts. Surg Today 2001;31:891–894.

    Article  Google Scholar 

  13. Takai S, Jin D, Nishimoto M, Sakaguchi M, Kirimura K, Yuda A, Miyazaki M. Cilostazol suppresses intimal formation in dog grafted veins with reduction of angiotensin II-forming enzymes. Eur J Pharmacol 2001;411:301–304.

    Article  PubMed  CAS  Google Scholar 

  14. O’Brien JE Jr, Ormont ML, Shi Y, Wang D, Zalewski A, Mannion JD. Early injury to the media after saphenous vein grafting. Ann Thorac Surg. 1998;65:1273–1278.

    Article  PubMed  Google Scholar 

  15. Hayashi S, Morishita R, Matsushita H, Nakagami H, Taniyama Y, Nakamura T, et al. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension 2000;35:237–243.

    PubMed  CAS  Google Scholar 

  16. Indorfi C, Di Lorenzo E, Rapacciuolo A, Stingone AM, Stabile E, Leccia A, et al. 8-Chloro-cAMP inhibited smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo. J Am Coll Cardiol 2000;36:288–293.

    Article  Google Scholar 

  17. Garg UC, Hassid A. Nitric oxide-generating vasodilator and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat smooth muscle cells. J Clin Invest 1989;83:1774–1777.

    Article  PubMed  CAS  Google Scholar 

  18. Holm AM, Andersen CB, Haunso S, Hansen PR. Effects of Larginine on vascular smooth muscle cell proliferation and apoptosis after balloon injury. Scand Cardiovasc J 2000;34:28–32.

    Article  PubMed  CAS  Google Scholar 

  19. Nishihara H, Hwang M, Kizaka-Kondoh S, Eckmann L, Insel PA. Cyclic AMP promotes CREB-dependent induction of the cellular inhibitor of apoptosis protein-2 and suppresses apoptosis of colon cancer cells through ERK1/2 and p38 MAPK. J Biol Chem. 2004;279:26176–26183.

    Article  PubMed  CAS  Google Scholar 

  20. Aharoni D, Dantes A, Oren M, Amsterdam A. cAMP-mediated signals as determinants for apoptosis in primary granulosa cells. Exp Cell Res. 1995;218:271–282.

    Article  PubMed  CAS  Google Scholar 

  21. Duprez E, Gjertsen BT, Bernard O, Lanotte M, Doskeland SO. Antiapoptotic effect of heterozygously expressed mutant RI (Ala336→Asp) subunit of cAMP kinase I in a rat leukemia cell line. J Biol Chem 1993;268:8332–8340.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kudo, F.A., Kondo, Y., Muto, A. et al. Cilostazol suppresses neointimal hyperplasia in canine vein grafts. Surg Today 39, 128–132 (2009). https://doi.org/10.1007/s00595-008-3819-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-008-3819-2

Key words

Navigation